We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Non-Invasive Gut Tests Could Help Diagnose Inflammatory Bowel Disease and Colon Cancer

By LabMedica International staff writers
Posted on 15 Feb 2024
Print article
Image: Mucus contains vital data to help address inflammatory bowel disease and colon cancer (Photo courtesy of 123RF)
Image: Mucus contains vital data to help address inflammatory bowel disease and colon cancer (Photo courtesy of 123RF)

New research is set to simplify and make gut health monitoring less invasive by focusing on an often-ignored yet readily available source: the mucus in our digestive tract that ultimately becomes part of fecal matter.

Researchers at UBC Okanagan (Kelowna, BC, Canada) have developed a method to analyze vital gut health markers from fecal-adherent mucus, essentially the mucus that adheres to stool. This mucus, typically discarded in stool, is actually rich in data about gut health. The team has pioneered a non-invasive approach to study MUC2, a key protein found in the stool that plays a significant role in gut health. MUC2 is a glycoprotein with numerous sugar chains that creates a protective mucus barrier in the intestines. This barrier is essential for defending the gut against harmful microbes and toxins and is integral to digestive health.

Previously, it was believed that this crucial molecule could only be extracted through invasive and painful methods like biopsies or surgical tissue removal. However, this study has revealed that mucus is a natural component of human stool, meaning it can be painlessly obtained and at levels not possible before at any time and that too non-invasively. A deeper understanding of MUC2 could pave the way for breakthroughs in the treatment and prevention of gut-related diseases, potentially improving the daily health of millions.

“MUC2 is like the silent star in our guts. It’s constantly working to protect us, and its proper functioning is crucial for our overall health,” said researcher Dr. Kirk Bergstrom. “We can use these new methods to visualize mucus-microbiota interactions and how they go wrong in various diseases, like inflammatory bowel diseases and colon cancer.”

Related Links:
UBC Okanagan

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
Nutating Mixer
Enduro MiniMix

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.